We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.53B
1-Year Est. Return 154.61%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+154.61%
3 Year Est. Return
+564.07%
5 Year Est. Return
+985.88%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$441M
Cap. Flow
+$174M
Cap. Flow %
6.85%
Top 10 Hldgs %
44.81%
Holding
120
New
30
Increased
23
Reduced
22
Closed
28

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$84.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$57.5M
3
EW icon
Edwards Lifesciences
EW
+$38.1M
4
ABT icon
Abbott
ABT
+$36.5M
5
UNH icon
UnitedHealth
UNH
+$31.5M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$49.3M
2
BTSG icon
BrightSpring Health Services
BTSG
+$38.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$30.6M
4
CNC icon
Centene
CNC
+$18.7M
5
FMS icon
Fresenius Medical Care
FMS
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.27%
2 Miscellaneous 3.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KARD
76
Kardigan Inc
KARD
$1.38B
$4.77M 0.19%
+200,000
New +$4.62M
BNTX icon
77
BioNTech
BNTX
$24.7B
$4.65M 0.18%
+50,000
New +$4.71M
INSP icon
78
Inspire Medical Systems
INSP
$2.04B
$4.46M 0.18%
+100,000
New +$4.74M
TRVI icon
79
Trevi Therapeutics
TRVI
$2.05B
$3.73M 0.15%
+200,000
New +$2.91M
IDYA icon
80
IDEAYA Biosciences
IDYA
$3.54B
$3.73M 0.15%
+100,000
New +$3.06M
CLDX icon
81
Celldex Therapeutics
CLDX
$2.44B
$3.72M 0.15%
+100,000
New +$3.23M
SVRA icon
82
Savara
SVRA
$1.03B
$3.7M 0.15%
600,000
– –
RLMD icon
83
Relmada Therapeutics
RLMD
$409M
$3.46M 0.14%
500,000
+50,000
+11% +$349K
MOBI
84
Mobia Medical
MOBI
$302M
$3.35M 0.13%
+250,000
New +$3.24M
SION
85
Sionna Therapeutics
SION
$236M
$3.3M 0.13%
75,000
+25,000
+50% +$1M
MANE
86
Veradermics Inc
MANE
$4.87B
$3.07M 0.12%
+25,000
New +$2.34M
IKT icon
87
Inhibikase Therapeutics
IKT
$287M
$2.74M 0.11%
1,350,000
– –
RZLT icon
88
Rezolute
RZLT
$376M
$2.6M 0.1%
500,000
-1,500,000
-75% -$5.57M
DNLI icon
89
Denali Therapeutics
DNLI
$3.26B
$2.57M 0.1%
+100,000
New +$2.05M
TENX icon
90
Tenax Therapeutics
TENX
$67.7M
$2.43M 0.1%
167,000
– –
OLMA icon
91
Olema Pharmaceuticals
OLMA
$766M
$1.25M 0.05%
100,000
-50,000
-33% -$670K
AURA icon
92
Aura Biosciences
AURA
$622M
$1.21M 0.05%
+170,000
New +$1.22M
AZN icon
93
AstraZeneca
AZN
$258B
– –
-250,000
Closed -$49.3M
CAPR icon
94
Capricor Therapeutics
CAPR
$486M
– –
-200,000
Closed -$6.08M
CELC icon
95
Celcuity
CELC
$3.89B
– –
-80,000
Closed -$9.13M
COO icon
96
Cooper Companies
COO
$10.5B
– –
-150,000
Closed -$10.7M
CYTK icon
97
CALL
Cytokinetics
CYTK
$8.99B
– –
-1,000,000
Closed -$65.9M
DNTH icon
98
Dianthus Therapeutics
DNTH
$4.95B
– –
-150,000
Closed -$12.6M
DXCM icon
99
DexCom
DXCM
$32.7B
– –
-175,000
Closed -$11M
ELAN icon
100
Elanco Animal Health
ELAN
$11.1B
– –
-550,000
Closed -$13.2M
1 2 3
4
5

Similar funds

VWA
Visionary Wealth Advisors O'fallon, Illinois $2.53B AUM 24.4% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.54B AUM 18.96% 1-Year Est. Return
QT
Quantbot Technologies New York $2.54B AUM 22.25% 1-Year Est. Return
LMIM
Lockheed Martin Investment Management Bethesda, Maryland $2.53B AUM 37.62% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.54B AUM 23.56% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.54B AUM 17.62% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.52B AUM 26.26% 1-Year Est. Return

Integral Health Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Integral Health Asset Management held 120 positions worth $2.53B, up 21% from $2.09B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $174M of net new capital in Q2 2026, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Abbott: 400,000 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BrightSpring Health Services, an estimated $38.9M trimmed.

  • Integral Health Asset Management's largest Q2 2026 buy was Abbott: 400,000 shares worth $36.3M.
  • Integral Health Asset Management added most to CVS Health in Q2 2026, an estimated $84.8M increase.
  • Integral Health Asset Management's biggest Q2 2026 reduction was BrightSpring Health Services, cutting an estimated $38.9M.
  • Integral Health Asset Management fully exited AstraZeneca in Q2 2026, selling an estimated $49.3M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $2.53B portfolio in Q2 2026.
  • Integral Health Asset Management opened 30 new positions and closed 28 in Q2 2026.
  • Integral Health Asset Management's portfolio value rose 21% quarter-over-quarter to $2.53B.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.